aTyr Pharma（股票代码：ATYR）周一盘后股价大跌5.32%，主要原因是该公司宣布其肺部疾病药物efzofitimod在一项后期研究中未能达到主要目标。
根据公司公告，efzofitimod在治疗肺肉瘤病患者的3期临床试验中，未能显示出与安慰剂相比在48周后每日类固醇用量削减幅度上的统计学显著差异。具体数据显示，服用高剂量药物的患者平均每天减少类固醇用量至2.79毫克/千克，而服用安慰剂的患者平均每天减少类固醇用量至3.52毫克/千克。
这一结果对aTyr Pharma打击不小，导致其股价在盘后交易中大幅下挫。肺肉瘤病是一种影响肺部和淋巴结的炎症性疾病，目前尚缺乏有效的治疗方法，efzofitimod曾被视为该领域的潜在突破性药物。
尽管临床试验结果不如预期，aTyr Pharma表示将与美国食品和药物管理局（FDA）进行接触，以确定该药物的未来发展方向。一些分析师认为，虽然未能达到主要终点，但efzofitimod在肺肉瘤病领域的前景尚未完全明朗，与监管机构沟通后可能仍有机会推进药物的申请进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.